Understanding ICH Q6A specifications for pharmaceutical starch excipients


Release time:

2026-11-11

Pharmaceutical Grade High Amylose Starch is a pharmacopoeia-compliant, amylose-rich maize starch for oral dosage forms. ICH Q6A does not list excipient monographs, yet it drives what a formulator must prove about every ingredient in a tablet. This guide shows how to turn those expectations into a workable specification for Pharmaceutical Grade High Amylose Starch, with data tables, a worked case and a UK sourcing route for 2026.

If you are comparing specifications and suppliers for a tablet project, the real question is rarely "what does the monograph say?" but "what must I add to it?" That gap is where most delays occur. In supplier documentation reviews for oral solid dose projects, a familiar pattern appears. The certificate of analysis satisfies a maize starch monograph but says nothing about amylose content, particle size or resistant starch, the very attributes that justify choosing a high amylose maize starch grade in the first place.

Article overview

This long-form guide explains how ICH Q6A principles apply when Pharmaceutical Grade High Amylose Starch is used as a pharmaceutical excipient starch. It covers scope, pharmacopoeial testing, impurity limits, functionality and UK procurement, with three data tables, a worked case, authoritative citations and a step-by-step qualification list. Information reflects guidance available in 2026; always check current pharmacopoeial editions.

What ICH Q6A covers and where excipients fit

ICH Q6A sets harmonised principles for specifications of new chemical drug substances and drug products; it contains no excipient monographs. Excipients such as Pharmaceutical Grade High Amylose Starch are controlled through pharmacopoeial standards and through the drug product specification that Q6A does govern. Put simply, Q6A defines the destination, and the excipient specification is part of the route.

Does ICH Q6A apply directly to excipients?

Strictly, no. The guideline addresses drug substances and drug products, and its decision trees cover tests such as description, identification, assay, impurities, water content, dissolution, disintegration, hardness, friability and microbial limits. Yet a regulator reviewing a tablet dossier will still ask how each excipient could change those outcomes. Why do so many teams overlook this link? Because the excipient section looks like paperwork, while the Q6A tests look like science. In reality, they form one chain of evidence.

The ICH wording is worth quoting directly:

"Specifications are critical quality standards that are proposed and justified by the manufacturer and approved by regulatory authorities as conditions of approval." — ICH Q6A, International Council for Harmonisation

Note the word "justified". For Pharmaceutical Grade High Amylose Starch, justification means showing that every test and limit protects a quality attribute of the finished tablet, not simply copying a monograph.

How Q6A, Q8, Q9 and Q10 connect to excipient control

Four ICH documents work together in practice. Q6A frames the finished-product tests. Q8(R2) asks you to link material attributes to critical quality attributes. Q9(R1) supplies the risk tools that decide which excipient attributes deserve tighter limits, and Q10 expects supplier oversight inside the quality system. For amylose-rich starch for tablets, the critical material attributes usually include amylose content, moisture, particle size distribution and bulk density, because they influence compaction, matrix behaviour and drug release.

Teams that document this link early, ideally in one risk-assessment table, tend to answer regulator queries far faster. Of course, a small immediate-release tablet with a potent, low-dose active may tolerate wider excipient variability, and the risk assessment should say so openly.

Pharmaceutical Grade High Amylose Starch: identity, grades and amylose content

Pharmaceutical Grade High Amylose Starch is a native maize starch whose amylose fraction sits far above the roughly 25–30% of standard maize starch, typically 55% to 70% or more, and which conforms to the relevant pharmacopoeial requirements. Its identity therefore rests on two pillars: monograph compliance and a verified amylose specification.

Pharmaceutical Grade High Amylose Starch refers to amylose-rich maize starch made and tested to excipient standards. It is supplied as a white, odourless high amylose corn starch powder. Its long linear amylose chains give distinct gelatinisation, film-forming and enzyme-resistance behaviour compared with ordinary starch, which is why formulators treat it as a functional material rather than a commodity filler.

What is the difference between high amylose starch and standard maize starch?

Starch is a mixture of two polymers: amylose is mostly linear, amylopectin is highly branched. A concise primer on high amylose starch and a broader summary of starch structure and properties cover the chemistry. Think of amylose as bundled rope and amylopectin as a tangled bush: the rope packs tightly and resists being pulled apart, while the bush opens easily. Raising amylose therefore changes how granules swell, how gels set and how enzymes attack them. Table 1 summarises the contrast.

Table 1. Indicative attributes of standard and high amylose maize starch

AttributeStandard maize starchHigh amylose maize starch (55% type)High amylose maize starch (70%+ type)
Typical amylose contentAbout 25–30%About 55%70% or higher
Gelatinisation behaviourModerate temperatureHigher temperatureMarkedly higher; often above 90 °C
Swelling in cold waterLowLowerLowest
Raw granule digestibilityLargely digestiblePartly resistantHigher resistant starch fraction (type 2)
Typical pharmaceutical roleFiller, binder, disintegrantBinder, filler, matrix modifierMatrix former, coating component

Values are indicative literature ranges; the certificate of analysis for each lot governs. In bench work, high amylose grades can be less free-flowing and more cohesive than standard maize starch, so flow checks such as Carr's index or angle of repose are worth adding to incoming tests.

Diagram comparing linear amylose and branched amylopectin inside a starch granule

Is high amylose starch a resistant starch?

Partly. Native granules rich in amylose are classed as resistant starch type 2, because their crystalline structure limits enzymatic hydrolysis in the small intestine. That is a physical property of the raw granule, not a health claim, and much of it disappears after cooking. The figure for amylose content itself is measured by iodine binding or enzymatic methods, and the ScienceDirect overview of amylose content explains why method choice can shift results.

Grade labelling deserves care. A product sold as amylose content 70% starch should carry a nominal value with a stated range on the certificate of analysis, plus the method name beside the number. Without that, two suppliers' "70%" figures cannot be compared. Pharmaceutical Grade High Amylose Starch at 55% suits applications needing moderate gel strength, whereas the 70%-plus tier is generally chosen where strong matrix behaviour or enzyme resistance is the goal.

Mapping Q6A test categories to pharmacopoeial tests for starch excipients

Each Q6A test category has a counterpart in the pharmacopoeial starch monographs of the USP-NF, the Ph. Eur. and the British Pharmacopoeia (BP), which incorporates Ph. Eur. texts. Where the monograph is silent, as it is on amylose content, the buyer adds a supplier-specific test and justifies the limit. Table 2 shows the mapping for Pharmaceutical Grade High Amylose Starch.

Table 2. Q6A-style attributes mapped to starch tests

Q6A-style attributeTypical pharmacopoeial test for starchAdditional test for high amylose grade
Description and identificationMicroscopy; iodine colour reactionAmylose content by named method
Water contentLoss on drying (monograph limit)Tighter internal limit; storage humidity data
Inorganic impuritiesSulfated ash or residue on ignition; ironICH Q3D risk assessment or ICP-MS data
Process residuesOxidising substances; sulfur dioxideDeclaration of processing aids
Microbial qualityTAMC, TYMC, absence of E. coli (Ph. Eur. 5.1.4; USP <61>/<62>)Seasonal lot trending
Physical propertiespH of suspension; foreign matterParticle size (laser diffraction), bulk and tapped density, flow, resistant starch (AOAC 2002.02)

Pharmacopoeial identity and purity tests

A USP/NF starch excipient monograph and the Ph. Eur. maize starch monograph (0344) both rely on microscopy, a characteristic iodine reaction, loss on drying, ash or residue on ignition, and limits for iron, oxidising substances and sulfur dioxide. Strictly, these texts describe maize starch generally. A claim of Ph. Eur. high amylose starch therefore usually means a maize starch that meets the monograph and also carries an amylose specification. As of 2026, I am not aware of a dedicated monograph for the high amylose type in either pharmacopoeia, so verify the editions in force before finalising your specification.

For UK-bound products, the BP is the recognised standard in Great Britain, while Northern Ireland arrangements follow Ph. Eur. Because the starch monograph content is aligned, one specification usually serves both markets. Confirm this with your regulatory affairs team.

Attributes the monograph leaves open

Particle size, bulk density, flowability, amylose content and resistant starch content typically sit outside monograph requirements, yet they govern compression and release. Why does that matter? Because two lots can both pass the monograph and still behave differently in the press. Add these as additional tests on the supplier specification and, for critical attributes, on your own incoming goods specification.

Testing every lot for every attribute is costly. A risk-based plan, with full testing on the first lots and reduced testing plus periodic verification afterwards, is a common and defensible approach for Pharmaceutical Grade High Amylose Starch.

Pharmaceutical Grade High Amylose Starch: impurities, microbial quality and contaminant control

Impurity control for Pharmaceutical Grade High Amylose Starch follows three streams: elemental impurities under ICH Q3D, residual solvents and process residues under ICH Q3C and supplier declarations, and microbial or biological contaminants under pharmacopoeial chapters. Because starch is an agricultural material, field and storage conditions matter as much as factory conditions.

Elemental impurities under ICH Q3D

Starch itself rarely carries heavy metal loads, but cereal crops can take up cadmium and arsenic from soil. Q3D asks for a risk assessment across all components of the product, and its Option 1 gives a permitted concentration for each excipient, assuming a daily product intake of no more than 10 g. Table 3 lists the oral limits for the principal elements.

Table 3. ICH Q3D oral permitted daily exposure (PDE) and Option 1 concentrations

ElementClassOral PDE (µg/day)Option 1 concentration (µg/g)
Cadmium150.5
Lead150.5
Arsenic (inorganic)1151.5
Mercury (inorganic)1303
Cobalt2A505
Vanadium2A10010
Nickel2A20020

Source: ICH Q3D(R2). Request ICP-MS data or a documented risk assessment from the supplier rather than assuming compliance.

Microbial quality, solvents, process aids and biological contaminants

Ph. Eur. general chapter 5.1.4 sets criteria for oral non-aqueous preparations of 103 CFU/g for total aerobic microbial count, 102 CFU/g for yeasts and moulds, and absence of E. coli in 1 g. USP <61>, <62> and <1111> offer parallel tests. Starch binds moisture and can support growth, so packaging integrity and storage humidity matter. Trend counts by season, because harvest year and ambient humidity can influence results.

Native starch does not use organic solvents, so Q3C residual solvents are usually a declaration-level topic. Modified starch for pharmaceutical use, such as pregelatinised or hydroxypropylated types, needs reagent residue control as well. Wet milling often involves sulfur dioxide steeping, which explains the monograph limit and why sulfites matter for labelling. Mycotoxins, pesticide residues and crop origin also deserve a written statement.

A non-GMO pharmaceutical starch declaration, backed by identity-preserved sourcing records, is frequently requested by European and UK customers, although it is not a pharmacopoeial requirement. Plant-derived starch carries negligible TSE risk, yet most quality teams still ask for a TSE/BSE statement for completeness. A one-page declaration costs little, while a missing one can stall an audit.

Functionality of amylose-rich starch for tablets and controlled release

Functionality tests are not Q6A requirements, yet they decide whether a grade performs. Amylose-rich starch for tablets can act as filler, binder, disintegrant or matrix former. At higher amylose levels it is also studied as a controlled release tablet excipient and in colon-targeted drug delivery starch systems. The right choice depends on the release profile you must achieve with Pharmaceutical Grade High Amylose Starch.

Can high amylose starch work as a tablet binder and disintegrant?

Yes, with limits. Native starch is a classic tablet binder and disintegrant, but the two roles differ. As a disintegrant it absorbs water and exerts swelling pressure; higher amylose granules swell less in cold water, so disintegrating power per percentage added can be lower than with standard maize starch. As a dry binder it contributes plasticity under compression, although results depend on moisture, active and process. Small pilot batches usually settle the question faster than literature review.

Moisture is the quiet variable. Starch equilibrates with ambient humidity and commonly holds around 10–15% water, so a blend made on a damp day differs from one made in dry conditions. Control humidity in dispensing rooms, and define a conditioning step if your process needs a tight moisture window.

Controlled release and colon-targeted delivery

Hydrated amylose can form a diffusion-limiting gel layer, which is why researchers since the late 1980s have examined high amylose starch as a matrix for sustained-release tablets. In coatings, amylose combined with a water-insoluble polymer such as ethylcellulose can resist gastric and small intestinal conditions yet be degraded by colonic bacterial amylases. Milojevic and colleagues reported this approach for 5-aminosalicylic acid pellets in the Journal of Controlled Release in 1996. That literature keeps colon-targeted work active, though routine commercial use remains limited.

Worked case: from functionality to specification

Consider a hypothetical but typical project, not a client record. A team wants a 200 mg matrix tablet that releases its active over about eight hours. A pilot batch made with standard maize starch erodes too quickly, so the team trials a 70% amylose grade. The risk assessment then flags four critical material attributes:

  • Amylose content, stated as a range with a named method
  • Moisture, set at the monograph limit plus a tighter internal limit
  • Particle size, as a D50 range by laser diffraction
  • Bulk and tapped density

Each attribute is tied to a Q6A product test: dissolution, hardness, friability and disintegration. Suppose dissolution shifts between two lots. Tracing the cause might show particle size, not amylose, as the driver, which would justify adding a D50 range to the incoming specification. The lesson generalises: let data, not assumption, decide which attribute is critical.

Qualifying a supplier and buying high amylose starch in the UK

To buy high amylose starch in the UK for pharmaceutical use, qualify the supplier through a documented sequence covering specification, documents, audit or questionnaire, sample testing and a quality agreement. The steps below reflect common practice in UK oral solid dose manufacturing, which follows MHRA expectations and the Orange Guide.

Seven steps to qualify a supplier of Pharmaceutical Grade High Amylose Starch

  1. Define the requirement: grade, amylose range and method, monograph compliance, particle size and packaging.
  2. Run a Q9 risk assessment to set excipient criticality and the level of GMP evidence needed.
  3. Request core documents: specification, certificate of analysis, process flow chart, sulfite, TSE/BSE and GMO statements, and Q3D data.
  4. Issue a supplier questionnaire and, for higher-risk materials, plan an on-site or remote audit.
  5. Test representative lots against the full specification, including amylose by the agreed method.
  6. Sign a quality agreement covering change notification, deviations and batch traceability.
  7. Set up ongoing monitoring: trending, periodic requalification and re-evaluation after any change.

UK medicines legislation, including the Human Medicines Regulations 2012, expects manufacturers to ensure that excipients are suitable for use. The EU guidelines on formalised excipient GMP risk assessment remain a widely used reference in UK quality systems. Your Qualified Person will expect that file to exist before certifying a batch.

What should a GMP certified starch supplier UK buyers can trust provide?

Ask for evidence rather than adjectives. A GMP statement should name the standard applied, for example the IPEC-PQG excipient GMP guide, EXCiPACT or an equivalent, and the certificate scope must cover the actual site and product. Verify certificates with the issuing body. If a supplier describes its starch as "pharma grade" yet offers only a food-safety certificate, treat that as a gap to close, not an automatic deal-breaker, since an audit and a quality agreement can sometimes bridge it.

Where can I buy high amylose starch in the UK?

UK buyers typically use one of three routes: a UK distributor holding stock, direct import from a manufacturer through a UK importer of record, or a custom development agreement. Searches for buy high amylose starch UK return mostly food-grade results, so filter by pharmacopoeial compliance early. Post-Brexit, check customs classification (starch falls under heading 1108), the regulatory status of natural substances under UK REACH, and lead times. Pricing in pounds sterling per kilogram depends on grade and volume, so request quotations for at least two pack sizes.

One example of an upstream source is Quanyin Xiangyu (Beijing Xiangyu), a breeder and supplier of high amylose maize that currently offers products at 71% and 55% amylose. The company states that it owns its high amylose varieties, with more than ten stable inbred lines, and operates a planting base of about 10,000 mu (roughly 667 hectares) with two grain cleaning lines, while contracting processing to established starch manufacturers. It sits within the strategic portfolio of a listed parent (stock code 300087) and was invited to join drafting of Chinese agricultural standards on resistant starch detection and glycaemic index foods. Buyers evaluating this or any source for pharmaceutical use should still request the documents above, because pharmacopoeial conformity, GMP status and GMO declarations must be confirmed site by site and lot by lot.

Conclusion: turning ICH Q6A principles into a usable starch specification

ICH Q6A does not write the excipient specification for you; it tells you what the finished tablet must prove. Pharmaceutical Grade High Amylose Starch meets that demand when monograph tests, an agreed amylose method, impurity control and functionality attributes are written down, justified and monitored.

Key takeaways

  • Q6A governs the drug product; excipient control flows from pharmacopoeias plus risk assessment.
  • Add the amylose content, particle size and density tests that monographs omit.
  • Use Q3D data and declarations for impurities, sulfites and GMO status.
  • Verify GMP evidence and sign a quality agreement before the first purchase.

Practical next steps for 2026

Begin with a gap analysis of your current certificate of analysis against Table 2, request Q3D data, and trial two amylose grades side by side. Pharmaceutical Grade High Amylose Starch rewards teams that treat specification as a development tool, not a purchasing formality. For any regulatory or health-related decision, consult qualified regulatory and quality professionals.

Frequently asked questions

Q: What is Pharmaceutical Grade High Amylose Starch?

A: It is maize starch with amylose content well above the 25–30% of standard maize starch, typically 55–70% or more, produced and tested to meet pharmacopoeial and GMP expectations for oral dosage forms. Buyers should confirm the amylose value and its test method on each certificate of analysis.

Q: Does ICH Q6A set limits for starch excipients?

A: No. ICH Q6A covers new drug substances and drug products. Excipient limits come from pharmacopoeial monographs such as USP-NF, Ph. Eur. and BP, plus supplier-specific tests justified through risk assessment under ICH Q8 and Q9 and linked to the finished-product specification.

Q: Which amylose content should I specify for a matrix tablet?

A: There is no universal figure. Grades around 55% and 70% or higher are commonly evaluated. Choose a nominal value and range based on pilot dissolution data, name the analytical method, and confirm lot-to-lot consistency before fixing limits in the specification.

Q: Can I buy Pharmaceutical Grade High Amylose Starch in the UK?

A: Yes, through UK distributors, direct importers or development agreements. Request the specification, certificate of analysis, GMP evidence, Q3D data and GMO and TSE statements, then qualify the supplier with a quality agreement. Confirm regulatory status with your Qualified Person.

Quanyin Xiangyu (Beijing) Biotechnology Co., Ltd.

Address: A/ Beijing, B/Jnan Shandong

Working hours: Monday to Friday 9:00-18:00 GMT+8

Phone: +86-15911081400  (WeChat)

E-mail: Pekingxiangyu@gmail.com

XIANGYU

Li (WeChat)

XIANGYU

Li (WeChat)


copyright © 2023 Quanyin Xiangyu (Beijing) Biotechnology Co., Ltd.  Powered by www.300.cn | TAGS

Business license